Drugs / conventional IPV
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT03902054 Comparator | Dec 2017 → May 2018 | postpoliomyelitis syndrome | Jiangsu Province Centers for Disease Control and Prevention | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | conventional IPV | “conventional IPV (cIPV, manufactured by Sanofi Pasteur)” NCT03902054 ↗ |
| Known as | cIPV | “conventional IPV (cIPV, manufactured by Sanofi Pasteur)” NCT03902054 ↗ |
| Known as | IPV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03902054 ↗ |
| Modality | Vaccine | “inactivated poliovirus vaccine (IPV) based on Sabin strains” PMID 32867698 ↗ Aug 2020 |
| Route | Intramuscular | “Three intramuscular injections of the investigational vaccine(0.5 ml)” NCT03902054 ↗ |